Bristol-Myers Squibb (NYSE:BMY) Holdings Raised by Biondo Investment Advisors LLC

Biondo Investment Advisors LLC boosted its holdings in Bristol-Myers Squibb (NYSE:BMY) by 0.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 142,200 shares of the biopharmaceutical company’s stock after purchasing an additional 1,260 shares during the quarter. Biondo Investment Advisors LLC’s holdings in Bristol-Myers Squibb were worth $8,043,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in BMY. Allstate Corp acquired a new stake in Bristol-Myers Squibb during the fourth quarter worth about $3,411,000. DnB Asset Management AS boosted its position in Bristol-Myers Squibb by 47.2% during the 4th quarter. DnB Asset Management AS now owns 709,131 shares of the biopharmaceutical company’s stock valued at $40,108,000 after purchasing an additional 227,521 shares during the period. denkapparat Operations GmbH acquired a new stake in Bristol-Myers Squibb in the fourth quarter worth $834,000. Orion Portfolio Solutions LLC lifted its stake in Bristol-Myers Squibb by 8.7% in the fourth quarter. Orion Portfolio Solutions LLC now owns 42,933 shares of the biopharmaceutical company’s stock valued at $2,428,000 after buying an additional 3,436 shares during the last quarter. Finally, Premier Fund Managers Ltd boosted its holdings in shares of Bristol-Myers Squibb by 9.5% during the fourth quarter. Premier Fund Managers Ltd now owns 186,300 shares of the biopharmaceutical company’s stock valued at $10,445,000 after acquiring an additional 16,100 shares during the period. Institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Stock Performance

Shares of NYSE BMY opened at $60.10 on Friday. The company has a market capitalization of $121.96 billion, a P/E ratio of -13.60, a price-to-earnings-growth ratio of 2.07 and a beta of 0.43. The business’s 50-day moving average price is $58.55 and its two-hundred day moving average price is $56.25. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $63.33. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. Analysts anticipate that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 1st. Investors of record on Friday, April 4th will be paid a dividend of $0.62 per share. The ex-dividend date is Friday, April 4th. This represents a $2.48 annualized dividend and a yield of 4.13%. Bristol-Myers Squibb’s payout ratio is -56.11%.

Insiders Place Their Bets

In related news, EVP Samit Hirawat acquired 1,823 shares of the stock in a transaction dated Friday, February 14th. The shares were acquired at an average price of $54.84 per share, for a total transaction of $99,973.32. Following the completion of the purchase, the executive vice president now owns 63,932 shares in the company, valued at approximately $3,506,030.88. The trade was a 2.94 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.09% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Citigroup boosted their target price on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a “neutral” rating in a research note on Tuesday, January 28th. Wells Fargo & Company boosted their price objective on Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an “equal weight” rating in a research report on Friday, February 7th. Bank of America restated a “neutral” rating and issued a $63.00 target price on shares of Bristol-Myers Squibb in a research report on Tuesday, December 10th. Cantor Fitzgerald increased their price target on Bristol-Myers Squibb from $50.00 to $55.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 4th. Finally, Truist Financial lifted their price objective on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating, four have assigned a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $57.86.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.